US 11,896,034 B2
Polypeptides having lysozyme activity, polynucleotides encoding same and uses and compositions thereof
Mikkel Klausen, Copenhagen (DK); Kirk Matthew Schnorr, Holte (DK); Lars Kobberoee Skov, Ballerup (DK); Soeren Nymand-Grarup, Copenhagen (DK); Marianne Thorup Cohn, Copenhagen (DK); Peter Bjarke Olsen, Copenhagen (DK); Ming Li, Beijing (CN); and Ye Liu, Beijing (CN)
Assigned to Novozymes A/S, Bagsvaerd (DK)
Filed by Novozymes A/S, Bagsvaerd (DK)
Filed on Mar. 25, 2021, as Appl. No. 17/212,019.
Application 17/212,019 is a division of application No. 16/463,205, granted, now 10,986,850, previously published as PCT/CN2017/117753, filed on Dec. 21, 2017.
Claims priority of application No. PCT/CN2016/111320 (WO), filed on Dec. 21, 2016; and application No. PCT/CN2017/075960 (WO), filed on Mar. 8, 2017.
Prior Publication US 2021/0212343 A1, Jul. 15, 2021
Int. Cl. A23K 20/189 (2016.01); A23K 20/174 (2016.01); A23K 20/22 (2016.01); A23K 20/24 (2016.01); A23K 20/20 (2016.01); A23K 50/30 (2016.01); A23K 50/75 (2016.01); A23K 10/30 (2016.01); C12N 9/36 (2006.01)
CPC A23K 20/189 (2016.05) [A23K 10/30 (2016.05); A23K 20/174 (2016.05); A23K 20/22 (2016.05); A23K 20/24 (2016.05); A23K 20/30 (2016.05); A23K 50/30 (2016.05); A23K 50/75 (2016.05); C12N 9/2462 (2013.01); C12Y 302/01017 (2013.01)] 7 Claims
 
1. A granule comprising one or more Glycoside Hydrolase Family 25 (GH25) polypeptides having lysozyme activity, wherein the polypeptide has improved activity compared to the activity of the polypeptide of SEQ ID NO: 39 and wherein the polypeptide is selected from the group consisting of:
(a) a polypeptide having at least 90% sequence identity to the polypeptide of SEQ ID NO: 3;
(b) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 6;
(c) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 9;
(d) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 12;
(e) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 18;
(f) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 21;
(g) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 24;
(h) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 30;
(i) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 33;
(j) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 38;
(k) a variant of the polypeptide selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 24, SEQ ID NO: 30, SEQ ID NO: 33 and SEQ ID NO: 38, wherein the variant has lysozyme activity and comprises one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in 1-20 positions;
(l) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), or (k), and a N-terminal and/or C-terminal histidine tag (His-tag) and/or histidine-glutamine tag (HQ-tag);
(m) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), or (k) and a N-terminal and/or C-terminal extension of between 1 and 10 amino acids; and
(n) a fragment of the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), or (k) or having lysozyme activity and having at least 90% of the length of the mature polypeptide.